NeoChord Names J. Alex Martin Chairman of the Board

ST. LOUIS PARK, Minn., Jan. 23, 2017 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the appointment of […]

Read On ›

First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation

ST. LOUIS PARK, Minn., Nov. 09, 2016 (GLOBE NEWSWIRE) —  NeoChord, Inc., a privately-held medical technology company leading the advancement of minimally invasive valve repair for degenerative mitral regurgitation (DMR), today announced the first use […]

Read On ›

NeoChord Receives FDA Approval to begin Clinical Trial for Treatment of Degenerative Mitral Valve Regurgitation

ST. LOUIS PARK, Minn.–(BUSINESS WIRE)–NeoChord, Inc. today announced that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to begin a prospective, multicenter, randomized clinical trial for […]

Read On ›

David H. Adams, MD and Michael A. Borger, MD, PhD to Serve as National Principal Investigators for NeoChord’s U.S. Pivotal Trial

ST. LOUIS PARK, Minn.–(BUSINESS WIRE)–NeoChord, Inc., a leader in advancing the treatment of minimally invasive repair of degenerative mitral valve regurgitation (DMR) without the use of cardiopulmonary bypass, today announced that David H. Adams, MD, […]

Read On ›

NEOCHORD SECURES $20 MILLION SERIES C FINANCING

EDEN PRAIRIE, MN, June 9, 2015—NeoChord Inc. – a medical technology company, announced today it has closed an oversubscribed $20 million Series C financing round led by Deerfield Management, with participation from Baird Capital’s Venture […]

Read On ›

NeoChord Appoints David Chung as President and CEO

EDEN PRAIRIE, Minn., June 24, 2014—NeoChord, a medical device company focused on minimally invasive mitral valve repair, announced today that it has appointed David H. Chung as President and CEO, effective immediately, replacing John Seaberg, […]

Read On ›

NeoChord Crosses 100th Patient Milestone; Appoints Michael Dale to Board of Directors

EDEN PRAIRIE, MN, April 4, 2014—NeoChord Inc., a developer of minimally invasive devices and procedures for mitral valve repair, today announced the treatment of its 100th patient.  “This is an important achievement for our Company, […]

Read On ›

NeoChord receives CE marking for DS1000 mitral valve repair device and plans first enrollments in TACT Registry for Q1 2013.

Initial registry training and proctoring to be provided by Leipzig Heart Center, Mayo Clinic and University of Pittsburgh Medical Center. TACT Trial results, recently reported at TCT and EACTS, show good safety and efficacy for […]

Read On ›

NeoChord Inc. Obtains Exclusive Rights to State-of-the-Art, Award-Winning ‘Augmented Reality’ Imaging Technology from Western University’s Robarts Research Institute

EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Robust navigation platform integrates real-time transesophageal echo (TEE) with a magnetic tracking system that guides a surgeon to virtual images of target anatomy. “The ‘NeoNav’ imaging platform offers faster and easier navigation […]

Read On ›

NeoChord Completes Enrollment for ‘TACT’ Clinical Trial

September 10, 2012 10:00 AM Eastern Daylight Time EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–   Acute and chronic results using NeoChord’s sternal-sparing, beating-heart, mitral valve repair system to implant artificial chordae tendinae are encouraging. NeoChord: “The 30-patient TACT […]

Read On ›

Two heart-repair device firms pull in $7M

Minnetonka, Minn. (August 4, 2011) – Minnesota companies continue to pull in venture capital, with two multimillion-dollar money raises disclosed in recent U.S. Securities and Exchange Commission filings. Minnetonka-based NeoChord recently raised $5 million and […]

Read On ›